BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33832921)

  • 21. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of
    Forlenza CJ; Zhang Y; Yao J; Benayed R; Steinherz P; Ramaswamy K; Kessel R; Roshal M; Shukla N
    Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30455225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
    Watanabe K
    Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
    Anoop P; Atra A
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.
    de Rooij JD; Hollink IH; Arentsen-Peters ST; van Galen JF; Berna Beverloo H; Baruchel A; Trka J; Reinhardt D; Sonneveld E; Zimmermann M; Alonzo TA; Pieters R; Meshinchi S; van den Heuvel-Eibrink MM; Zwaan CM
    Leukemia; 2013 Dec; 27(12):2280-8. PubMed ID: 23531517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
    Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
    Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several?
    Lu G; Altman AJ; Benn PA
    Cancer Genet Cytogenet; 1993 Jun; 67(2):81-9. PubMed ID: 8330276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
    Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitive detection of GATA1 mutations using complementary DNA-based analysis for transient abnormal myelopoiesis associated with the Down syndrome.
    Mizuta S; Yamane N; Mononobe S; Watanabe A; Kitamura R; Takahara T; Matsushima C; Yoshida A; Okamoto S; Tanaka K; Iwai A; Ikegawa A; Wada T; Usami I; Maihara T; Komai T; Heike T; Nishida Y; Kobayashi K
    Int J Lab Hematol; 2022 Apr; 44(2):349-355. PubMed ID: 34761527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute Megakaryocytic Leukemia.
    McNulty M; Crispino JD
    Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
    Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang HY; Chen W
    Cytometry B Clin Cytom; 2015; 88(4):244-52. PubMed ID: 25361478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.
    Ono R; Hasegawa D; Hirabayashi S; Kamiya T; Yoshida K; Yonekawa S; Ogawa C; Hosoya R; Toki T; Terui K; Ito E; Manabe A
    Eur J Pediatr; 2015 Apr; 174(4):525-31. PubMed ID: 25266042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
    Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
    Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Courses of Two Pediatric Patients with Acute Megakaryoblastic Leukemia Harboring the CBFA2T3-GLIS2 Fusion Gene.
    Ishibashi M; Yokosuka T; Yanagimachi MD; Iwasaki F; Tsujimoto SI; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Kajiwara R; Tanaka F; Goto H; Yokota S
    Turk J Haematol; 2016 Dec; 33(4):331-334. PubMed ID: 27094503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
    Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
    Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
    Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
    Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.